Fuji Shigeo, Löffler Jürgen, Einsele Hermann, Kapp Markus
a Department of Haematopoietic Stem Cell Transplantation , National Cancer Center Hospital , Tokyo , Japan.
b Department of Internal Medicine II , Division of Hematology/Oncology, University Hospital of Würzburg , Würzburg , Germany.
Virulence. 2016 Nov 16;7(8):939-949. doi: 10.1080/21505594.2016.1207038. Epub 2016 Jul 6.
The outcome after allogeneic haematopoietic stem cell transplantation (allo-HSCT) has significantly improved during the last decades. However, opportunistic infections such as viral and mold infections are still a major obstacle for cure. Within this field, adoptive T cell therapy against pathogens is a promising treatment approach. Recently, the techniques to develop T cell products including pathogen-specific T cells have been sophisticated and are now available in accordance to good manufacturing practice (GMP). Here, we aim to summarize current knowledge about adoptive T cell therapy against viral and mold infections.
在过去几十年中，异基因造血干细胞移植（allo-HSCT）后的疗效有了显著改善。然而，病毒和霉菌感染等机会性感染仍然是治愈的主要障碍。在这一领域，针对病原体的过继性T细胞疗法是一种很有前景的治疗方法。最近，开发包括病原体特异性T细胞在内的T细胞产品的技术已经成熟，并且现在已按照药品生产质量管理规范（GMP）投入使用。在此，我们旨在总结目前关于针对病毒和霉菌感染的过继性T细胞疗法的知识。
